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http://www.biomedcentral.com/1472-6963/13/162RESEARCH ARTICLE Open AccessHospital laboratory reporting may be a barrier to
detection of ‘microsize’ myocardial infarction in
the US: an observational study
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Ronald J Prineas3 and Todd M Brown4Abstract
Background: International guidelines recommend that the decision threshold for troponin should be the 99th
percentile of a normal population, or, if the laboratory assay is not sufficiently precise at this low level, the level at
which the assay achieves a 10% or better coefficient of variation (CV). Our objectives were to examine US hospital
laboratory troponin reports to determine whether either the 99th percentile or the 10% CV level were clearly
indicated, and whether nonconcordance with these guidelines was a potential barrier to detecting clinically
important microscopic or ‘microsize’ myocardial infarctions (MIs). To confirm past reports of the clinical importance
of microsize MIs, we also contrasted in-hospital, 28-day and 1-year mortality among those with microsize and
nonmicrosize MI.
Methods: In the REasons for Geographic And Racial Differences in Stroke national prospective cohort study
(n=30,239), 1029 participants were hospitalized for acute coronary syndrome (ACS) between 2003–2009. For each
case, we recorded all thresholds of abnormal troponin on the laboratory report and whether the 99th percentile or
10% CV value were clearly identified. All cases were expert adjudicated for presence of MI. Peak troponin values
were used to classify MIs as microsize MI (< five times the lowest listed upper limit of normal) and nonmicrosize MI.
Results: Participants were hospitalized at 649 acute care US hospitals, only 2% of whose lab reports clearly
identified the 99th percentile or the 10% CV level; 52% of reports indicated an indeterminate range, a practice that
is no longer recommended. There were 183 microsize MIs and 353 nonmicrosize MIs. In-hospital mortality tended
to be lower in the microsize than in the nonmicrosize MI group (1.1 vs. 3.6%, p = 0.09), but 28-day and 1-year
mortality were similar (2.5% vs. 2.7% [p = 0.93] and 5.2% vs. 4.3% [p = 0.64], respectively).
Conclusions: Current practices in many US hospitals created barriers to the clinical recognition of microsize MI,
which was common and clinically important in our study. Improved hospital troponin reporting is warranted.
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Guidelines for defining myocardial infarction (MI) have
long recommended that events be classified using a com-
bination of the clinical presentation, electrocardiogram
(ECG) or cardiac imaging findings, and biomarkers [1-4].
Troponin is the preferred biomarker due to its high
specificity for cardiac muscle [1-4]. The risk for mortality
and cardiovascular events is increased with even modest
troponin elevations [5-9]; therefore, for several years,
American and European cardiology societies, the National
Heart, Lung and Blood Institute, the Centers for Disease
Control and Prevention, and others have recommended
defining abnormal troponin as any value above the 99th
percentile for healthy individuals [1-4,10-14], culminating
in the publication of the Universal Definition of MI in
2007 [1-3].
A problem acknowledged by the Universal Definition
and other preceding guidelines is that some assays may
not be reliable at levels as low as the 99th percentile.
Troponin levels in normal reference populations are very
close to zero, and recent advances in biomarker assays
permit detection of levels as low as 0.006 μg/L [15].
However, precision at very low levels may not be accep-
table [15]. Therefore, until assays achieve greater preci-
sion at very low levels and become more standardized,
experts have recommended defining the threshold for
abnormal troponin as either the 99th percentile of a nor-
mal reference population or the level at which the assay
achieves acceptable precision, defined by a coefficient of
variation (CV) of 10% or better [1-4,10-14]. All values of
troponin above this threshold are recommended to be
considered myocardial necrosis, which, together with a
characteristic rising and/or falling pattern, is used in
clinical decision-making to classify an event as an MI.
In order to apply this recommendation, the 99th per-
centile or 10% CV level must be clearly identified on
hospital laboratory troponin reports and labeled as the
decision threshold. However, many hospitals have for
years reported an “indeterminate range,” which was use-
ful in interpreting troponin relative to creatine kinase
(CK)-MB fractions when troponin was first introduced.
The upper limit of this indeterminate range was the
World Health Organization (WHO) cut-point corre-
sponding to abnormal CK-MB, and many reports con-
tinue to provide interpretive guidelines recommending
that troponin values above this WHO cut-point repre-
sent a high likelihood of MI. Clinicians interpreting such
reports today may be challenged to identify the more
current, lower guideline-recommended decision thresh-
old. Furthermore, as ST elevation MI is declining while
non-ST elevation MI remains common [16,17], troponin
levels are increasingly the deciding factor in determining
whether acute coronary syndrome (ACS) is classified as
an MI. In this context, the troponin laboratory report iscritical for appropriately classifying and risk stratifying
MI events. However, guideline concordance in hospital
laboratory troponin reports has to our knowledge not
been examined.
We studied US hospital laboratory troponin practices
in the REasons for Geographic And Racial Differences in
Stroke (REGARDS) study, a large national prospective
cohort study. We also examined mortality risks associ-
ated with very low, or ‘microsize,’ troponin peak MIs
relative to MIs with higher peak troponin levels to both
confirm the risks that have been described in other po-
pulations and to highlight the potential clinical relevance
of hospital troponin reporting practices.
Methods
The REGARDS study is prospectively following 30,239
individuals for cardiovascular events and mortality to
better understand regional and racial influences on stroke
and MI mortality. Details of the study are described else-
where [18]. Briefly, recruitment was conducted from
2003–2007 using commercially available lists and a com-
bination of mail and telephone contact to recruit English-
speaking, community-dwelling adults aged 45 and older
living in the 48 contiguous US. Baseline data collection in-
cluded telephone surveys and in-home exams, and living
participants are telephoned every six months and asked if
they were hospitalized with subsequent medical records
retrieval. Deaths were detected from reaching next of kin
at a scheduled follow-up, online sources (e.g., Social Se-
curity Death Index), or the National Death Index. Medical
records were reviewed by a team of experts, who adjudi-
cated MI events using a standardized approach modeled
on major epidemiologic studies [4]. The study protocol
was reviewed and approved by the University of Alabama
Institutional Review Board, and all participants provided
informed consent.
We included the first hospitalization for ACS for each
participant occurring between 2003 and 2009. ACS was
defined as an urgent presentation of signs and symptoms
suggestive of acute coronary ischemia resulting in hos-
pitalization. For each case, we examined the hospital la-
boratory troponin report for documentation of the 99th
percentile for healthy adults or the 10% CV level for the
assay utilized and whether either was clearly identified
as the decision threshold for abnormal troponin. We
also examined whether an indeterminate range was pro-
vided, a practice that is no longer recommended [1].
Expert adjudicators classified cases as ACS without MI
or ACS with MI following approaches used in most large
epidemiology studies [4]. For MI, medical records were
examined for the presence of signs or symptoms suggest-
ive of ischemia; a rising and/or falling pattern in cardiac
troponin or creatine phosphokinase-MB over ≥6 hours
with a peak value ≥ twice the upper limit of normal; and
Safford et al. BMC Health Services Research 2013, 13:162 Page 3 of 7
http://www.biomedcentral.com/1472-6963/13/162ECG changes consistent with ischemia or MI, guided by
the Minnesota code [4]. By convention, adjudicators used
as the troponin decision threshold the 99th percentile or
10% CV value if clearly identified on the report, or if not
clearly identified, twice the lowest listed upper limit of
normal (ULN). MIs were adjudicated as definite, probable,
or possible, and only definite or probable MI events were
included in this study as MI events. The highest and low-
est levels of troponin and upper limits of normal were also
recorded.
After adjudication, cases were further classified into
microsize MI or usual MI based on peak troponin levels.
Microsize MI was defined as an adjudicated MI with
peak troponin no more than five times the lowest listed
ULN, and usual MIs were all other adjudicated MIs. We
examined clinical characteristics of individuals and in-
hospital, 28-day and 1-year age, sex, and race-adjusted
mortality in each of the three ACS groups of no MI,
microsize MI and usual MI.Statistical analyses
We examined differences in participant characteristics
among the three ACS groups, no MI, microsize MI,
and usual MI. Available characteristics included sociode-
mographics (age, sex, race) and medical conditions (hyper-
tension, defined as systolic blood pressure ≥140 mmHg
or diastolic blood pressure ≥90 mmHg or treated with
antihypertensive medications; diabetes, defined as
fasting blood glucose ≥126 mg/dl, random blood glu-
cose ≥200 mg/dl, or being treated with diabetes medi-
cations; and a history of heart disease, defined as a
self-reported history of MI or coronary intervention,
or evidence of MI on ECG at baseline). Physiologic
variables included body mass index, low-density lipo-
protein cholesterol (LDL-C) levels, high density lipo-
protein cholesterol (HDL-C) levels, triglyceride levels,
and creatinine levels.
After conducting a descriptive analysis, we constructed
a logistic regression model to examine associations with
microsize MI relative to usual MI, entering the above
clinical characteristics into a multivariable model that
included all cases of MI. Mortality for ACS, microsize
MI, and usual MI was calculated by dividing the number
of deaths in the period among those at risk. Specifically,
in-hospital mortality was the number of deaths prior to
discharge among those hospitalized; 28-day mortality
was the number of deaths at 28 days among those sur-
viving to discharge; and 1-year mortality was the number
of deaths at 365 days among those surviving to 28 days.
These proportions were adjusted for age, race, and
sex and tested for statistically significant differences.
All analyses were carried out using SAS version 9.1,
Cary, North Carolina.Results
Variations in hospital laboratory troponin reporting
No ULN for troponin was provided in 35 laboratory re-
ports, and these hospitals were excluded, resulting in the
inclusion of 649 different hospitals located in 490 US
cities in 45 states. The type of troponin was troponin-I
in 76% of hospitals and troponin-T in 7%; the type of
troponin was not specified in 17% of reports.
Sixteen (2%) hospitals specifically identified either the
99th percentile or the 10% CV level, but only one hos-
pital advised clinicians that the 99th percentile should be
used as the decision threshold for defining myocardial
necrosis. A single ULN was provided in 48% of hospitals
without specification of whether it was the 99th percent-
ile or the 10% CV level. More than one ULN was pro-
vided in the remaining hospitals. When more than one
threshold was reported, it was often in the context of
ranges accompanied by interpretive language (e.g., 0–0.04
“normal”; 0.05-1.5 “indeterminate”; >1.5 “consistent with
acute MI”). In 13% of the hospitals, there were four or
more such ranges.
The name of the manufacturer of the troponin assay
would theoretically permit clinicians to examine the ta-
bles available online at the International Federation of
Clinical Chemists (IFCC) website for 99th percentile
values and 10% CV levels (see Additional file 1). How-
ever, the name of the assay was provided in only 15 hos-
pitals, and the IFCC was mentioned in only one report.
Because only a single manufacturer (Roche) distrib-
uted troponin-T assays during the study period, the 99th
percentile and 10% CV values can be approximated
using the IFCC table even when no manufacturer is spe-
cified on the laboratory report; the decision threshold
during the observation period should have been 0.03
[15,19]. However, in half (n = 38) of troponin-T hos-
pital laboratory reports, 0.1 was provided as the ULN.
This higher value corresponded to the assay’s WHO
cut-point, which is no longer recommended as a deci-
sion threshold.
Additional evidence that some hospital laboratories
were providing thresholds well above the recommended
decision thresholds came from 56 reports in which the
ULN provided was higher than the 10% CV level of any
assay reported by the IFCC [15,19]. These results suggest
that even among the 48% of labs with a single ULN in
our study, there is considerable uncertainty around whe-
ther the listed ULN is actually the guideline-concordant
decision threshold.
Clinical implications of microsize MI
Of the 1,029 cases of ACS included in the analysis, 493
were classified as ACS without MI, 183 as microsize
MIs, and 353 as usual MIs (Table 1). There were propor-
tionately more black participants in the microsize MI
Table 1 Baseline characteristics of 1029 patients presenting with acute coronary syndrome (ACS)
ACS without MI Microsize MI Usual MI P-value†
Tn* < ULN ULN ≤ Tn < 5×ULN Tn ≥ 5×ULN
(n = 493) (n = 183) (n = 353)
Age≥ 65 years,% 62.3 68.3 66.9 0.73
Black Race,% 39.8 38.3 28.6 0.03
Female Gender,% 50.9 37.7 32.3 0.21
Obese,% 49.1 40.4 33.4 0.11
Hypertension,% 81.1 76.0 73.7 0.56
Diabetes,% 36.7 39.9 32.0 0.07
History of Heart Disease,% 46.7 48.6 38.8 0.03
Triglyceride ≥200 mg/dl,% 18.5 20.8 20.7 0.99
High Density Lipoprotein Cholesterol ≤40 mg/dl,% 33.5 33.3 41.4 0.07
Low Density Lipoprotein Cholesterol ≥160 mg/dl,% 7.5 5.5 9.9 0.08
Mean creatinine, mg/dL (SD) 1.0 (0.4) 1.0 (0.5) 1.2 (1.1) 0.03
Framingham CHD Risk score, Mean (SD) 12.6 (11.3) 14.1 (9.6) 16.5 (12.7) 0.07
*Tn = Troponin, ULN = Upper Limit of Normal, MI = Myocardial Infarction.
†Chi-square test for categorical variables and student t-test for continuous variables used to test differences between microsize and usual MI groups. See text for
definition of medical conditions. Bold italicized characteristics differed statistically between microsize and usual MI groups.
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with microsize MI had a history of heart disease, and the
mean creatinine was lower in the microsize MI group.
Framingham Coronary Heart Disease (CHD) risk scores
demonstrated a trend for a graded increase in risk across
the groups.
The logistic regression analysis of all cases of MI re-
vealed that black race, history of CHD, and creatinine
were independent predictors of microsize MI relative to
usual MI (Table 2).
In the mortality analysis, in-hospital mortality was
lower for microsize MIs compared with usual MIs, tren-
ding toward statistically significant difference (p = 0.09),
and in-hospital mortality was statistically different for
those with ACS without MI compared to both microsize
MI or usual MI (Figure 1). However, although 28-day
case fatality was not statistically different across MI
groups, mortality trended towards significant differ-
ences between the ACS without MI versus the otherTable 2 Multivariable logistic regression results testing assoc
Crude odds rat
Black vs. White race 1.55
Female vs. Male 1.27
Obese vs. Not Obese 1.35
Diabetes vs. No Diabetes 1.41
History of heart disease vs. none 1.49
Low density lipoprotein cholesterol ≥160 vs. <160 mg/dL 0.53
High density lipoprotein cholesterol ≤40 vs. >40 mg/dL 0.71
Creatinine, per mg/dL 0.76
For definitions of medical conditions, see text. Bolded italicized results indicate stattwo groups. At one year, both types of MI had higher
mortality relative to those with ACS without MI, and
the rate was slightly higher for microsize MIs than for
usual MIs, though that difference was not statistically
significant.
Discussion
We found major deviations from guideline recommen-
dations for troponin laboratory reporting in our study.
Laboratory reports only rarely identified a 99th percentile
or 10% CV level, and more than half of hospitals identi-
fied an indeterminate range classifying MI based on a
higher threshold than the guideline-recommended ap-
proach [1-3,20]. In this context, many microsize MIs
may be difficult to recognize clinically.
Although our study was not able to examine the pro-
portion of microsize MIs missed clinically by treating
physicians as a result of hospital reporting practices, it is
likely that some of these events were in fact not treatediations between having a microsize versus usual MI
ios Adjusted odds ratios (95% Confidence interval) P-value
1.62 (1.06, 2.48) 0.03
0.94 (0.62, 1.44) 0.78
1.15 (0.76, 1.73) 0.52
1.19 (0.78, 1.81) 0.43
1.63 (1.11, 2.39) 0.01
0.52 (0.24, 1.10) 0.09
0.78 (0.52, 1.16) 0.22



















ACS w/o MI Microsize MI Usual MI
Figure 1 Adjusted mortality for acute coronary syndrome without MI, microsize MI, and usual MI patients ACS=Acute Coronary
Syndrome. ACS without MI=ACS with peak troponin below upper limit of normal (ULN) and adjudicated as no myocardial infarction (MI).
Microsize MI=adjudicated MI with peak troponin above ULN but less than 5 times ULN. Usual MI=adjudicated MI with peak troponin 5 or more
times above ULN. All mortality rates include only those surviving the previous period; e.g., 28-day mortality includes only those discharged alive.
Total number of deaths: ACS without MI (in-hospital = 0, 28-day = 5, 1-year = 11); Microsize MI (in-hospital = 2, 28-day = 7, 1-year = 12); Usual MI
(in-hospital = 7, 28-day = 12, 1-year = 15). ACS w/o MI vs. Microsize MI: In-Hospital p = 0.02 28-Day p = 0.26 1-Year p = 0.02. ACS w/o MI vs. Usual
MI: In-Hospital p < 0.01 28-Day p = 0.11 1-Year p = 0.02. Microsize MI vs. Usual MI: In-Hospital p = 0.09 28-Day p = 0.93, 1-Year p = 0.64.
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as “normal” has significant long-term prognostic impli-
cations. The higher long-term mortality risk we observed
for those suffering microsize MIs was similar to past re-
ports in which the in-hospital risks were low, but by one
month and one year were similar to those with usual
MIs [21,22]. This finding underscores both the import-
ance of long-term risk factor management in patients
with microsize MIs and the relatively low short-term
risks [1-4,21,23-26].
A recent report from Scotland illustrates the clinical
importance of detecting microsize MIs [22]. Investiga-
tors at the Royal Infirmary in Edinburgh took advantage
of the introduction of a more sensitive troponin assay to
study clinical management and outcomes among indi-
viduals analogous to our microsize MI group. In their
study, the focus was on individuals whose peak troponin
elevations were above the threshold for the new assay
(0.05) and below the threshold for the older, less sensi-
tive assay (0.20), both before and after changes in lab re-
ports. They found that, after introduction of the lower
decision threshold on lab reports, secondary preven-
tive measures increased by 15-30% in the microsize MI
group but remained similar for those in the usual MI or
no MI groups. They also reported reductions in clinical
outcomes, including the rate of MIs and deaths at 3 and
12 months in the group with microsize MIs after intro-
duction of the lower threshold on lab reports. While this
is an observational study from a single site, it does pro-
vide evidence of the potential impact of appropriate
troponin reporting to optimize clinical management.These findings together with our results suggest that
improved reporting of hospital troponin results in the
US is warranted; the US now has a system of public
accountability for the quality of health care that provides
a ready infrastructure to enact rapid change. A quality
indicator assessing whether the recommended decision
threshold is clearly identified on laboratory reports and
assessing whether indeterminate ranges are used could
be added rapidly to standards for accreditation by the
Joint Commission or to the Centers for Medicare and
Medicaid Services’ pay-for-performance programs, such
as the Premier Hospital Quality Incentive Demonstra-
tion [27,28].
Our study included a large proportion of black partici-
pants, which has not been the case in previous reports
stemming from non-US samples [21]. Our finding that
black participants had 62% higher odds for microsize
MIs raises concerns that some microsize MIs among
black individuals may not be recognized clinically. In-
deed, the last decade has demonstrated a concerning
widening of the CHD mortality disparity between black
and white people in the US, with white mortality rates
declining faster than black rates [29]. Similar to past re-
ports, we found that those with a past history of CHD
were also more likely to be in the microsize MI group
[21]. The clinical consequences of overlooking a microsize
MI in individuals with a history of CHD may be mini-
mized because many such patients may already be receiv-
ing secondary prevention, including aggressive smoking
cessation counseling, lipid management, beta blockers, or
anti-platelet therapy. On the other hand, as many as half
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continue their medications [30-32]; thus, an overlooked
microsize MI may translate into a missed opportunity to
redouble secondary preventive efforts in these individuals.
Our study’s limitations include our inability to examine
how many cases classified as microsize MI by our rigorous
adjudication methods were also recognized as MI by the
treating physicians. We also did not have available the
99th percentile or 10% CV value at each hospital at the
time of the event. Like other large epidemiology studies,
we had to rely on clinical laboratories from many hospitals
to classify MI and, given the variations we described, it is
possible that, while state-of-the art and rigorous, the adju-
dication process under-detected some microsize MIs. This
challenge would bias our results towards finding less dif-
ference in mortality rates than may actually exist; thus, the
mortality risks we describe may underestimate the true
risks. Our team of experts only classified events as MI if
there was a clear rising and/or falling pattern of troponin,
and perennial low level elevations seen in conditions such
as heart failure or renal failure would therefore not have
been classified as MI; however, it is possible that some
misclassification could have occurred. Unfortunately, this
study was not designed to detect differences in clinical
management in microsize and usual MIs, but recent re-
ports suggest that this may be an important issue [33]. Fu-
ture studies should examine what proportion of microsize
MIs were not managed as acute MIs. Another limitation
is the context of a national epidemiologic cohort study;
thus, participants may not be representative of the US
population. Although we included 649 hospitals, they may
not be representative of all US acute care hospitals. In
addition, event accrual may permit future analyses of
CHD or cardiovascular disease deaths, in contrast to the
all-cause mortality we used in this study.
Conclusions
Many US hospital laboratories did not report 99th per-
centiles or 10% CV levels in their troponin reports as
recommended by national and international guidelines,
complicating the detection of microsize MIs. This may
result in misclassification of some individuals with MI,
preventing optimal clinical management. Our study con-
firms the excess risks associated with microsize MI de-
scribed in other populations, emphasizing the importance
of recognizing these cases clinically. Prompt attention to
improving the quality of hospital laboratory reporting of
patient troponin results is warranted.
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